Search Results - "Gjertsen, B."

Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy by Gjertsen, B T, Schöffski, P

“…Owing to their integral involvement in cell cycle regulation, the Polo-like kinase (Plk) family, particularly Plk1, has emerged as an attractive therapeutic…”
Get full text

HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia by Kontro, M, Kumar, A, Majumder, M M, Eldfors, S, Parsons, A, Pemovska, T, Saarela, J, Yadav, B, Malani, D, Fløisand, Y, Höglund, M, Remes, K, Gjertsen, B T, Kallioniemi, O, Wennerberg, K, Heckman, C A, Porkka, K

“…Inhibitors of B-cell lymphoma-2 (BCL-2) such as venetoclax (ABT-199) and navitoclax (ABT-263) are clinically explored in several cancer types, including acute…”
Get full text

Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia by McCormack, E, Haaland, I, Venås, G, Forthun, R B, Huseby, S, Gausdal, G, Knappskog, S, Micklem, D R, Lorens, J B, Bruserud, Ø, Gjertsen, B T

“…Although TP53 mutations are rare in acute myeloid leukemia (AML), wild type p53 function is habitually annulled through overexpression of MDM2 or through…”
Get full text

Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients by Hjorth-Hansen, H, Stentoft, J, Richter, J, Koskenvesa, P, Höglund, M, Dreimane, A, Porkka, K, Gedde-Dahl, T, Gjertsen, B T, Gruber, F X, Stenke, L, Eriksson, K M, Markevärn, B, Lübking, A, Vestergaard, H, Udby, L, Bjerrum, O W, Persson, I, Mustjoki, S, Olsson-Strömberg, U

“…Dasatinib (DAS) and interferon-α have antileukemic and immunostimulatory effects and induce deep responses in chronic myeloid leukemia (CML). We assigned 40…”
Get full text

Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS by Ossenkoppele, G. J., Breems, D. A., Stuessi, G., van Norden, Y., Bargetzi, M., Biemond, B. J., A von dem Borne, P., Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B., Graux, C., Huls, G., Janssen, J. J. J. W., Jaspers, A., Jongen-Lavrencic, M., de Jongh, E., Klein, S. K., van der Klift, M., van Marwijk Kooy, M., Maertens, J., Michaux, L., van der Poel, M. W. M., van Rhenen, A., Tick, L., Valk, P., Vekemans, M. C., van der Velden, W. J. F. M., de Weerdt, O., Pabst, T., Manz, M., Löwenberg, B.

“…More effective treatment modalities are urgently needed in patients with acute myeloid leukemia (AML) of older age. We hypothesized that adding lenalidomide to…”
Get full text

Safety and efficacy of the combination of pegylated interferon- alpha 2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients by Hjorth-Hansen, H, Stentoft, J, Richter, J, Koskenvesa, P, Hoglund, M, Dreimane, A, Porkka, K, Gedde-Dahl, T, Gjertsen, B T, Gruber, F X, Stenke, L, Eriksson, K M, Markevaern, B, Luebking, A, Vestergaard, H, Udby, L, Bjerrum, O W, Persson, I, Mustjoki, S, Olsson-Stromberg, U

“…Dasatinib (DAS) and interferon- alpha have antileukemic and immunostimulatory effects and induce deep responses in chronic myeloid leukemia (CML). We assigned…”
Get full text

Update on the randomised phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma by Schuster, C., Gausdal, G., Gjertsen, B.T., Lorens, J., Straume, O.

Get full text

Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia by Kontro, M, Kuusanmäki, H, Eldfors, S, Burmeister, T, Andersson, E I, Bruserud, Ø, Brümmendorf, T H, Edgren, H, Gjertsen, B T, Itälä-Remes, M, Lagström, S, Lohi, O, Lundán, T, Martí, J M L, Majumder, M M, Parsons, A, Pemovska, T, Rajala, H, Vettenranta, K, Kallioniemi, O, Mustjoki, S, Porkka, K, Heckman, C A

Get full text

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients by Mustjoki, S, Richter, J, Barbany, G, Ehrencrona, H, Fioretos, T, Gedde-Dahl, T, Gjertsen, B T, Hovland, R, Hernesniemi, S, Josefsen, D, Koskenvesa, P, Dybedal, I, Markevärn, B, Olofsson, T, Olsson-Strömberg, U, Rapakko, K, Thunberg, S, Stenke, L, Simonsson, B, Porkka, K, Hjorth-Hansen, H

“…Chronic myeloid leukemia (CML) stem cells appear resistant to tyrosine kinase inhibitors (TKIs) in vitro, but their impact and drug sensitivity in vivo has not…”
Get full text

Tunneling nanotube (TNT) formation is independent of p53 expression by Andresen, V, Wang, X, Ghimire, S, Omsland, M, Gjertsen, B T, Gerdes, H H

Get full text

Review: genetic models of acute myeloid leukaemia by McCormack, E, Bruserud, O, Gjertsen, B T

“…The use of genetically engineered mice (GEM) have been critical in understanding disease states such as cancer, and none more so than acute myelogenous…”
Get full text

NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib by Sopper, S, Mustjoki, S, Gjertsen, B T, Giles, F, Hochhaus, A, Janssen, J J W M, Porkka, K, Wolf, D

Get full text

Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia by Ånensen, N, Hjelle, S M, Van Belle, W, Haaland, I, Silden, E, Bourdon, J-C, Hovland, R, Taskén, K, Knappskog, S, Lønning, P E, Bruserud, Ø, Gjertsen, B T

“…The wild-type tumor-suppressor gene TP53 encodes several isoforms of the p53 protein. However, while the role of p53 in controlling normal cell cycle…”
Get full text

Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS by Ossenkoppele, G. J., Breems, D. A., Stuessi, G., van Norden, Y., Bargetzi, M., Biemond, B. J., A von dem Borne, P., Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B., Graux, C., Huls, G., Janssen, J. J. J. W., Jaspers, A., Jongen-Lavrencic, M., de Jongh, E., Klein, S. K., van der Klift, M., van Marwijk Kooy, M., Maertens, J., Michaux, L., van der Poel, M. W. M., van Rhenen, A., Tick, L., Valk, P., Vekemans, M. C., van der Velden, W. J. F. M., de Weerdt, O., Pabst, T., Manz, M., Löwenberg, B.

“…An amendment to this paper has been published and can be accessed via a link at the top of the paper…”
Get full text

In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL by Laukkanen, S, Grönroos, T, Pölönen, P, Kuusanmäki, H, Mehtonen, J, Cloos, J, Ossenkoppele, G, Gjertsen, B, Øystein, B, Heckman, C, Heinäniemi, M, Kontro, M, Lohi, O

Get full text

Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels by Hatfield, K J, Hovland, R, Øyan, A M, Kalland, K H, Ryningen, A, Gjertsen, B T, Bruserud, Ø

“…The balance between proangiogenic Angiopoietin-1 (Ang-1) and the antagonistic Ang-2 is important both for leukemogenesis and chemosensitivity in human acute…”
Get full text

Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation by Hallenborg, P, Feddersen, S, Francoz, S, Murano, I, Sundekilde, U, Petersen, R K, Akimov, V, Olson, M V, Lozano, G, Cinti, S, Gjertsen, B T, Madsen, L, Marine, J-C, Blagoev, B, Kristiansen, K

“…The role of the E3 ubiquitin ligase murine double minute 2 (Mdm2) in regulating the stability of the p53 tumor suppressor is well documented. By contrast,…”
Get full text

Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis by Gavasso, S, Gjertsen, BT, Anderssen, E, Myhr, KM, Vedeler, C

“…Background: Immunogenicity of recombinant interferon-β (IFN-β) is a known complication in the therapy of relapsing–remitting multiple sclerosis (RRMS)…”
Get full text

Animal models of acute myelogenous leukaemia - development, application and future perspectives by MC CORMACK, E, BRUSERUD, Ø, GJERTSEN, B. T

“…From the early inception of the transplant models through to contemporary genetic and xenograft models, evolution of murine leukaemic model systems have been…”
Get full text

P548: BEMCENTINIB COMBINED WITH LOW‐DOSE CYTARABINE IS EFFICACIOUS AND WELL TOLERATED IN RELAPSED AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY. UPDATES FROM THE ONGOING PHASE II TRIAL (NCT02488408) by Loges, S., Heuser, M., Chromik, J., Sutamtewagul, G., Kapp‐Schwoerer, S., Crugnola, M., Di Renzo, N., Lemoli, R., Mattei, D., Ben‐Batalla, I., Waizenegger, J., Rieckmann, L.‐M., Janning, M., Imbusch, C. D., Beumer, N., Micklem, D., Gorcea‐Carson, C., Lawson, G., Nautiyal, J., Deharo, S., Fiedler, W., Alvarado‐Valero, Y., Gjertsen, B.

Get full text